Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

Premier Anti-Aging Co., Ltd. (4934.T)

Compare
726.00
-75.00
(-9.36%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 4934.T
  • Previous Close 801.00
  • Open 794.00
  • Bid 717.00 x --
  • Ask 726.00 x --
  • Day's Range 706.00 - 794.00
  • 52 Week Range 641.00 - 949.00
  • Volume 90,200
  • Avg. Volume 31,450
  • Market Cap (intraday) 6.331B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 7.67
  • EPS (TTM) 94.67
  • Earnings Date Jun 11, 2025 - Jun 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 830.00

Premier Anti-Aging Co., Ltd. engages in the planning, development, import, export, mail order, wholesale, and retail of cosmetics and health foods in Japan. It offers its products under the DUO, CANADEL, Immuno, Sitrana, and Clayence brands. The company was incorporated in 2009 and is headquartered in Tokyo, Japan.

www.p-antiaging.co.jp

229

Full Time Employees

July 31

Fiscal Year Ends

Recent News: 4934.T

View More

Performance Overview: 4934.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4934.T
10.37%
Nikkei 225 (^N225)
15.33%

1-Year Return

4934.T
10.81%
Nikkei 225 (^N225)
15.07%

3-Year Return

4934.T
81.78%
Nikkei 225 (^N225)
21.79%

5-Year Return

4934.T
87.20%
Nikkei 225 (^N225)
89.56%

Compare To: 4934.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4934.T

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    6.33B

  • Enterprise Value

    2.80B

  • Trailing P/E

    7.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.35

  • Price/Book (mrq)

    0.94

  • Enterprise Value/Revenue

    0.15

  • Enterprise Value/EBITDA

    1.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.29%

  • Return on Assets (ttm)

    7.67%

  • Return on Equity (ttm)

    12.40%

  • Revenue (ttm)

    18.24B

  • Net Income Avi to Common (ttm)

    783M

  • Diluted EPS (ttm)

    94.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.31B

  • Total Debt/Equity (mrq)

    26.50%

  • Levered Free Cash Flow (ttm)

    1.94B

Research Analysis: 4934.T

View More

Company Insights: 4934.T

Research Reports: 4934.T

View More

People Also Watch